

MEDIA RELEASE



MUTABILIS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT INFECTIONS CAUSED BY WHO CRITICAL PRIORITY PATHOGENS

Collaboration sets sight on a new age where novel classes of antibiotics and personalized health care options will be available

(PARIS, France) – Mutabilis, a biotech based in Romainville, France, announced today that it has entered into a Research Collaboration and License Agreement with Roche on its 2G-Dabocins program. Mutabilis has extensive experience in the development of novel non-beta-lactam PBP-targeting antibacterial drugs, or ‘Dabocins’, to treat the worst Gram-negative bacterial infections. Dabocins show stability against beta-lactamase hydrolysis and could lead to the discovery of a new family of antibiotics, paving the way into a new Platinum Age where novel classes of antibiotics and timely personalized health care options will be available.

Under the agreement, Mutabilis will lead all activities until entry into GLP tox, whereupon Roche would take over all further research activities and development with the aim to commercialize a new antibiotic to treat multidrug-resistant infections.

“The collaboration with Roche is a great achievement for the Mutabilis team. It emphasizes the potential of Dabocins to play a key role to circumvent Gram-negative bacterial infections,” said **Wandrille Ract-Madoux, CEO of Mutabilis**. “We are very confident that by joining forces with Roche, we will contribute to developing novel antibiotics, resetting the clock on antimicrobial resistance.”

James H. Sabry, Ph.D., Global Head of Pharma Partnering at Roche, said, “The new partnership with Mutabilis underlines our strong commitment to the development of new therapies and diagnostics to combat infectious diseases. We look very much forward to working with Mutabilis towards a new Platinum Age of antibiotics where new classes of antibiotics will be available for patients in need.”

ABOUT MUTABILIS

Mutabilis is a privately held French biopharmaceutical company developing novel non-beta-lactam PBP-targeting antibacterial drugs (Dabocins) to combat the most difficult-to-treat Gram-negative bacterial infections. Dabocins are derived from the non-natural diazabicyclooctane scaffold and show remarkable stability against beta-lactamase hydrolysis. Mutabilis' team has unique expertise in the derivation and characterization of this scaffold. Mutabilis' pipeline includes EBL-1463, a novel single-agent intravenous antibiotic against carbapenem-resistant Enterobacterales, supported by ENABLE (ND4BB/IMI) and CARB-X, and 2G-DAB, a 2nd generation Dabocin program supported by the Novo Repair Impact Fund which aims to discover the next generation Dabocin covering both Enterobacterales and non-fermenters. For more information, please visit <https://mutabilis.fr/>.

Carb-x : <https://carb-x.org>

Enable : <http://nd4bb-enable.eu>

Novo Repair Impact Fund : <https://www.repair-impact-fund.com>



MUTABILIS

Mutabilis Media Contact:

Virginie Fagart
info@mutabilis.fr